JAK3 and neoplasm: Our identification of JAK3 mutations is consistent with its established role in MF pathogenesis; however, reported frequencies vary across studies, with 8.3% in MF tumor-stage samples in McGirt et al. and 33.3% in MF patients in Bastidas Torres et al., underscoring the influence of sequencing platforms and cohort selection on the reported genomic landscape [5,17].